Table 3.

Between-trial comparison of progression-free and overall survival for ibrutinib vs. obinutuzumab + chlorambucil (Bayesian approach)

Population	HR [95% CrI] P(HR <1)
	PFS by IRC assessment	PFS by investigator assessment	Overall survival
RESONATE-2 (ITT)	0.85	0.48	0.40
	[0.44, 1.63]	[0.22, 1.02]	[0.10, 1.54]
	0.69	0.97	0.91
RESONATE-2 (after exclusion)a	0.50	0.31	0.16
	[0.22, 1.15]	[0.12, 0.81]	[0.02, 1.34]
	0.95	0.99	0.95
RESONATE-2 (matched n = 13)	0.24	0.12	0.21
	[0.04, 1.35]	[0.02, 0.97]	[0.00, 8.89]
	0.95	0.98	0.79
RESONATE-2 (matched n = 12)	0.34	0.43	0.20
	[0.11, 1.12]	[0.16, 1.18]	[0.01, 5.16]
	0.96	0.95	0.83

CrI credible interval, HR hazard ratio, ITT intention to treat population, n number of variables matched, P(HR <1) probability that the HR is less than 1, i.e., ibrutinib is better than obinutuzumab + chlorambucil

^aExcludes patients from RESONATE-2 with CIRS ≤6 and creatinine clearance ≥70 mL/min, patients with creatinine clearance <30 mL/min, and SLL patients